RxDoctor Payments Data

Bruce Mann, MD

Pain Medicine · Tamarac, FLNPI 1285607911

Payments from drug & device makers

$7,408in general payments, 2019–2025

Across 285 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Medtronic$724
  • Scilex Pharmaceuticals Inc.$600
  • Relievant Medsystems, Inc.$487
  • Forte Bio-pharma LLC$450
  • SPR Therapeutics, Inc$369
  • plus $3K from 33 others

What the payments were for

  • Travel & lodging$2263%
  • Food & beverage$7,18297%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,408 in reported general payments places this provider in the 70th percentile of 596 pain medicine providers in Florida.

See all pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$543,760
Medicare patients
644
Services billed
8,311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide42$87,056
Xtampza ErOxycodone Myristate118$78,441
PercocetOxycodone Hcl/Acetaminophen12$61,642
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,271$41,214
OxycontinOxycodone Hcl27$39,931
RoxybondOxycodone Hcl16$30,177
BelbucaBuprenorphine Hcl42$28,522
MovantikNaloxegol Oxalate61$25,668
ZtlidoLidocaine58$25,041
Oxycodone Hcl722$17,664
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen496$13,568
Buprenorphine32$11,884
Nucynta ErTapentadol Hcl13$9,793
Lidocaine101$8,904
Pregabalin338$8,702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er$294$116,756173 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,384$87,05642 claims
Protega Pharmaceutials IncRoxybond$114$30,17716 claims
Redhill Biopharma Inc.Movantik$94$25,66861 claims
Scilex Pharmaceuticals Inc.Ztlido$600$25,04158 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate, Buprenorphine Hcl$26$16,292145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 596 pain medicine providers in Florida.

Other pain medicine in Tamarac

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →